IXHL Stock Analysis: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$3.62
0.05 (1.40%)
▲
5d:
+9.2%
30d:
+22.71%
90d:
+2.84%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Oct 05, 2026
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $3.62, which is considered extended relative to its 30-day fair value range of $2.97 to $3.38. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.5) compared to its historical average (3.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IXHL is in a uptrend. The price is approaching resistance at $3.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IXHL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.25 (+411.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IXHL is in a uptrend. The price is approaching resistance at $3.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IXHL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.25 (+411.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.97 -
$3.38
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 411.1% below Wall St target ($18.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.97 -
$3.38
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.09
Resistance Level
$3.65
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$18.25
(+411.1%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-1.5 vs 3.7
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 2:08 PM ET
Data refreshes hourly during market hours. Next update: 3:08 PM
Data refreshes hourly during market hours. Next update: 3:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
